Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe T-Cell therapy Market, by End User
1.4.2 Europe T-Cell therapy Market, by Indication
1.4.3 Europe T-Cell therapy Market, by Therapy Type
1.4.4 Europe T-Cell therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
Chapter 4. Europe T-Cell therapy Market by End User
4.1 Europe Hospitals Market by Country
4.2 Europe Cancer Treatment Centers Market by Country
Chapter 5. Europe T-Cell therapy Market by Indication
5.1 Europe Lymphoma Market by Country
5.2 Europe Acute Lymphocytic Leukemia Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe T-Cell therapy Market by Therapy Type
6.1 Europe CAR T-Cell Therapy Market by Country
6.2 Europe T-Cell therapy Market by CAR T-Cell Therapy Type
6.2.1 Europe Axicabtagene Ciloleucel Market by Country
6.2.2 Europe Tisagenlecleucel Market by Country
6.2.3 Europe Brexucabtagene Autoleucel Market by Country
6.2.4 Europe Others Market by Country
6.3 Europe T-Cell Receptor (TCR)-Based Market by Country
Chapter 7. Europe T-Cell therapy Market by Country
7.1 Germany T-Cell therapy Market
7.1.1 Germany T-Cell therapy Market by End User
7.1.2 Germany T-Cell therapy Market by Indication
7.1.3 Germany T-Cell therapy Market by Therapy Type
7.1.3.1 Germany T-Cell therapy Market by CAR T-Cell Therapy Type
7.2 UK T-Cell therapy Market
7.2.1 UK T-Cell therapy Market by End User
7.2.2 UK T-Cell therapy Market by Indication
7.2.3 UK T-Cell therapy Market by Therapy Type
7.2.3.1 UK T-Cell therapy Market by CAR T-Cell Therapy Type
7.3 France T-Cell therapy Market
7.3.1 France T-Cell therapy Market by End User
7.3.2 France T-Cell therapy Market by Indication
7.3.3 France T-Cell therapy Market by Therapy Type
7.3.3.1 France T-Cell therapy Market by CAR T-Cell Therapy Type
7.4 Russia T-Cell therapy Market
7.4.1 Russia T-Cell therapy Market by End User
7.4.2 Russia T-Cell therapy Market by Indication
7.4.3 Russia T-Cell therapy Market by Therapy Type
7.4.3.1 Russia T-Cell therapy Market by CAR T-Cell Therapy Type
7.5 Spain T-Cell therapy Market
7.5.1 Spain T-Cell therapy Market by End User
7.5.2 Spain T-Cell therapy Market by Indication
7.5.3 Spain T-Cell therapy Market by Therapy Type
7.5.3.1 Spain T-Cell therapy Market by CAR T-Cell Therapy Type
7.6 Italy T-Cell therapy Market
7.6.1 Italy T-Cell therapy Market by End User
7.6.2 Italy T-Cell therapy Market by Indication
7.6.3 Italy T-Cell therapy Market by Therapy Type
7.6.3.1 Italy T-Cell therapy Market by CAR T-Cell Therapy Type
7.7 Rest of Europe T-Cell therapy Market
7.7.1 Rest of Europe T-Cell therapy Market by End User
7.7.2 Rest of Europe T-Cell therapy Market by Indication
7.7.3 Rest of Europe T-Cell therapy Market by Therapy Type
7.7.3.1 Rest of Europe T-Cell therapy Market by CAR T-Cell Therapy Type
Chapter 8. Company Profiles
8.1 Merck KGaA
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Johnson & Johnson
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental &Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Gilead Sciences, Inc.
8.4.1 Company overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Acquisition and Mergers:
8.4.4.3 Trials and Approvals:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.6.5.3 Trials and Approvals:
8.7 Sorrento Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Trials and Approvals:
8.8 Bristol Myers Squibb Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.5.2 Acquisition and Mergers:
8.8.5.3 Geographical Expansions:
8.8.5.4 Trials and Approvals:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.10. Immunocore Holdings plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Trials and Approvals:
Unique Offerings 